MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical firm centered on discovering, creating, and commercializing transformative therapies to remedy blindness ailments, introduced it can current on the H.C. Wainwright 22nd Annual World Funding Convention on Tuesday, September 15 at three p.m. ET.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will current just about to supply an replace on the event of Ocugen’s breakthrough modifier gene remedy platform in addition to its novel biologic product candidate.
He’ll spotlight Ocugen’s lead product candidate, OCU400, which has the potential to deal with many types of retinitis pigmentosa and simply acquired its fourth FDA orphan drug designation. Dr. Musunuri will share Ocugen’s current accomplishments and its upcoming deliberate close to and medium-term milestones.
Date: Tuesday, September 15, 2020
Time: 03:00 PM (Jap Time)
Webcast Hyperlink: https://wsw.com/webcast/hcw7/ocgn/1597167
The H.C. Wainwright 22nd Annual World Funding Convention will happen on September 14-16 just about.
Thanks for visiting! MyChesCo brings dependable data and assets to Chester County, Pennsylvania. Please contemplate supporting us in our efforts. Your beneficiant donation will assist us proceed this work and preserve it freed from cost. Present your assist immediately by clicking here and becoming a patron.